S169: CLINICAL AND MOLECULAR MARKERS FOR PREDICTING RESPONSE TO ROMIPLOSTIM TREATMENT IN LOWER-RISK MYELODYSPLASTIC SYNDROMES. (23rd June 2022) - Kubasch, A. S.; Giagounidis, A.; Metzgeroth, G.; Jonasova, A.; Herbst, R.; Diaz, J. M. T.; De Renzis, B.; Götze, K. S.; Huetter-Kroenke, M.-L.; Gourin, M.-P.; Slama, B.; Dimicoli-Salazar, S.; et al.